Target

• US 6,794,192 B2
• Filed: 06/28/2001
• Issued: 09/21/2004
• Est. Priority Date: 06/29/2000
• Status: Expired due to Fees

• Current Assignee: Pfizer Inc., Pfizer Products Incorporated (Pfizer Inc.)
• Original Assignee: Pfizer Inc.
• Inventors: Phillips, Stephen Charles, Ridden, John, Parums, Dinah
• Primary Examiner(s): Le, Long V.
• Assistant Examiner(s): Cheu, Jacob J.
• Application Number:
  US09/894,743
• Publication Number:
  US 20030040041A1
• Time in Patent Office: 1,181 Days
• Field of Search: 424/133.1, 424/134.1, 424/139.1, 424/146.1, 435/7.21, 435/240.27, 435/91.1, 436/547, 436/15
• US Class Current: 436/15
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: C07K 16/40 against enzymes
• CPC Class Codes: C12N 9/16 acting on ester bonds (3.1)
• CPC Class Codes: C12Q 1/44 involving esterase
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere
• CPC Class Codes: Y10T 436/105831 Protein or peptide standard or control [e.g., hemoglobin, etc.]

Abstract

The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.

Claims

1. An isolated target sequence, wherein said target sequence is comprising a polypeptide consisting of the sequence shown in SEQ ID NO:

1.

2. The isolated target sequence of claim 1 wherein said target sequence is immunologically reactive with an antibody.